We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 39.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$1.45B
$6.3M 0.08%
542,363
– –
INSM icon
52
Insmed
INSM
$22.4B
$6.08M 0.07%
304,050
-250,000
-45% -$3.7M
NVAX icon
53
Novavax
NVAX
$1.21B
$5.65M 0.07%
61,168
– –
CYTR
54
DELISTED
CytRx Corp
CYTR
$5.64M 0.07%
225,000
– –
CPRX
55
DELISTED
Catalyst Pharmaceutical
CPRX
$5.62M 0.07%
2,223,053
+1,653,200
+290% +$3.53M
RXDX
56
DELISTED
Ignyta, Inc.
RXDX
$5.19M 0.06%
571,000
– –
AMBI
57
DELISTED
Ambit Biosciences Corp
AMBI
$5.17M 0.06%
747,954
– –
BDSI
58
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.08M 0.06%
421,005
– –
STML
59
DELISTED
Stemline Therapeutics, Inc.
STML
$4.97M 0.06%
338,671
– –
ZGNX
60
DELISTED
Zogenix, Inc.
ZGNX
$4.72M 0.06%
293,800
– –
ACGN
61
DELISTED
Aceragen Inc
ACGN
$4.68M 0.06%
11,873
– –
LGND icon
62
Ligand Pharmaceuticals
LGND
$5.77B
$4.57M 0.06%
117,660
– –
RARE icon
63
Ultragenyx Pharmaceutical
RARE
$2.46B
$4.49M 0.06%
100,000
– –
KPTI icon
64
Karyopharm Therapeutics
KPTI
$155M
$4.38M 0.05%
6,273
+2,333
+59% +$1.09M
GALT icon
65
Galectin Therapeutics
GALT
$230M
$4.14M 0.05%
300,000
-200,000
-40% -$2.49M
CNCE
66
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$4.03M 0.05%
+398,800
New +$3.85M
AKTX
67
Akari Therapeutics
AKTX
$14.4M
$3.71M 0.05%
84
– –
IONS icon
68
Ionis Pharmaceuticals
IONS
$8.93B
$3.32M 0.04%
96,303
– –
ACHN
69
DELISTED
Achillion Pharmaceuticals
ACHN
$3.32M 0.04%
438,337
– –
ENTA icon
70
Enanta Pharmaceuticals
ENTA
$362M
$3.25M 0.04%
75,357
-5,600
-7% -$214K
VXRT
71
DELISTED
Vaxart
VXRT
$3.15M 0.04%
100,628
– –
ALDR
72
DELISTED
Alder Biopharmaceuticals
ALDR
$3.08M 0.04%
+153,350
New +$2.16M
LPCN icon
73
Lipocine
LPCN
$17.1M
$3.05M 0.04%
+29,412
New +$3.52M
TBRA
74
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$2.72M 0.03%
44,444
– –
MDWD icon
75
MediWound
MDWD
$184M
$2.56M 0.03%
+32,143
New +$2.62M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Baker Bros. Advisors held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Baker Bros. Advisors withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 43% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Baker Bros. Advisors's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Baker Bros. Advisors added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Baker Bros. Advisors's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Baker Bros. Advisors fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Baker Bros. Advisors's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Baker Bros. Advisors opened 7 new positions and closed 9 in Q2 2014.
  • Baker Bros. Advisors's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.